Seema A Bhat
Ohio State University Comprehensive Cancer Center LAO · Ohio State University Comprehensive Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Seema A Bhat as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:47 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT06965114 · Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell LeukemiaNational Cancer Institute (NCI) · recruiting · Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia, Refractory Hairy Cell Leukemia · principal investigator
- Ph2NCT06757647 · Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaSeema Bhat · recruiting · Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma · principal investigator
- Ph2NCT05417165 · Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic LeukemiaSeema Bhat · recruiting · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:47 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 9 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- The Ohio State University as a Lead Academic Organization (LAO) for the Experimental Therapeutics Clinical Trials NetworkUM1CA186712 · NCI · OHIO STATE UNIVERSITY · PI SUSANNE M ARNOLD, WILLIAM E. CARSON, Narendranath Epperla · fiscal years 2014 to 2026Named on NCT06965114
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 09:47 UTC. The ranking covers the 200 most relevant of 7 PubMed records, and a shared surname and initials can bring in a namesake. All 7 on PubMed
- Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia.J Clin Oncol · 202091 citationsRCR 3.7
- Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia.Cancer Discov · 202071 citationsRCR 2.9
- First-in-Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma.Cancer Discov · 202450 citationsRCR 6.2
- A Phase II Trial of Rituximab Combined With Pegfilgrastim in Patients With Indolent B-cell Non-Hodgkin Lymphoma.Clin Lymphoma Myeloma Leuk · 20185 citationsRCR 0.2